Janssen Pharmaceutica NV, of Beerse, Belgium, part of Johnson & Johnson, reported results from the PROSIPAL (Prevention of Relapse With Oral Antipsychotics Versus Injectable Paliperidone Palmitate) study at the European Congress of Psychiatry in Munich, showing Xeplion (paliperidone palmitate), a once-weekly, long-acting therapy, significantly lengthened the time to relapse during the two-year treatment phase, as well as significantly lowered relapse rates in people with schizophrenia, compared to treatment as usual with the investigators’ choice of oral antipsychotic treatment.